Medication info
Dapagliflozin Tablet 10 mg (Dapagliflozin Propanediol Hydrate)

Dapagliflozin Tablet 10 mg (Dapagliflozin Propanediol Hydrate)

Prescription medicationTabletOral
Ingredient · strength
Dapagliflozin Propanediol Hydrate›12.3mg / 1 tablet
Manufacturer / importer
Medica Korea Co., Ltd.
Appearance
Yellow, film-coated tablet with a two-sided convex diamond shape
Packaging
28 tablets/PTP [28 tablets (7 tablets/PTP x 4)]
Approval status
Active

MFDS item code 202300379 · Approved 2023.01.30 · Insurance code 646005670

Summary

Main use
Improvement of blood glucose control in type 2 diabetes mellitus; prevention of worsening chronic heart failure and chronic kidney disease
Who takes it
Adults · Children
Adult dose
Type 2 diabetes mellitus Monotherapy and add-on combination therapy The recommended dose of this medicine is 10mg once daily for monotherapy and add-on combination therapy with other glucose-lowering agents, including insulin. When this medicine is used in combination with insulin or insulin secretagogues such as sulfonylureas, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. Initial combination therapy For patients with no prior antidiabetic drug treatment, when administered in combination with metformin, the recommended initial dose of this medicine is 5mg once daily or 10mg once daily. Chronic heart failure and chronic kidney disease The recommended dose of this medicine is 10mg once daily. Special populations Renal impairment - eGFR less than 45mL/min/1.73m2: Use of this medicine to improve glycemic control is not recommended. - eGFR less than 25mL/min/1.73m2: Initiation of this medicine is not recommended in patients with chronic heart failure and chronic kidney disease. - Patients on dialysis: Do not administer this medicine. Hepatic impairment No dose adjustment is necessary in patients with mild or moderate hepatic impairment. For patients with severe hepatic impairment, a starting dose of 5mg is recommended. If well tolerated, this dose may be increased to 10mg. Older adults (≥65 years) Dose adjustment based on age is not recommended. Method of administration This medicine may be taken orally once daily at any time of day, with or without food. Tablets should be swallowed whole.
Child dose
The efficacy and safety of dapagliflozin in children under 18 years of age have not been established. No relevant data are available.

Ingredients

Manufacturer
Medica Korea Co., Ltd.

Efficacy & effects

Improvement of blood glucose control in type 2 diabetes mellitus; prevention of worsening chronic heart failure and chronic kidney disease

  • Type 2 diabetes
  • poor glycemic control
  • cardiovascular disease
  • cardiovascular risk factors
  • chronic heart failure
  • heart failure
  • chronic kidney disease
  • estimated glomerular filtration rate decline
  • end-stage kidney disease
View approved original text

This medication is used in conjunction with dietary and exercise therapy to improve glycemic control in patients with type 2 diabetes. Additionally, it helps reduce the risk of cardiovascular events in patients with type 2 diabetes who have insufficient glycemic control and have cardiovascular disease or risk factors. For patients with chronic heart failure, it is used alongside other standard therapies to reduce the risk of death from cardiovascular disease and hospitalization due to heart failure. It is also effective in slowing the progression to end-stage kidney disease and reducing the risk of death from cardiovascular disease in patients with chronic kidney disease. Therefore, this medication is used for the treatment of type 2 diabetes, chronic heart failure, and chronic kidney disease.

How to take

Adult dose

Type 2 diabetes mellitus Monotherapy and add-on combination therapy The recommended dose of this medicine is 10mg once daily for monotherapy and add-on combination therapy with other glucose-lowering agents, including insulin. When this medicine is used in combination with insulin or insulin secretagogues such as sulfonylureas, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. Initial combination therapy For patients with no prior antidiabetic drug treatment, when administered in combination with metformin, the recommended initial dose of this medicine is 5mg once daily or 10mg once daily. Chronic heart failure and chronic kidney disease The recommended dose of this medicine is 10mg once daily. Special populations Renal impairment - eGFR less than 45mL/min/1.73m2: Use of this medicine to improve glycemic control is not recommended. - eGFR less than 25mL/min/1.73m2: Initiation of this medicine is not recommended in patients with chronic heart failure and chronic kidney disease. - Patients on dialysis: Do not administer this medicine. Hepatic impairment No dose adjustment is necessary in patients with mild or moderate hepatic impairment. For patients with severe hepatic impairment, a starting dose of 5mg is recommended. If well tolerated, this dose may be increased to 10mg. Older adults (≥65 years) Dose adjustment based on age is not recommended. Method of administration This medicine may be taken orally once daily at any time of day, with or without food. Tablets should be swallowed whole.

Child dose

The efficacy and safety of dapagliflozin in children under 18 years of age have not been established. No relevant data are available.

Precautions

This medication should not be used in patients with allergies to the active ingredient or excipients. It is also not recommended for patients with type 1 diabetes or diabetic ketoacidosis. Containing lactose anhydrous, it should not be used in patients with lactose intolerance or certain genetic metabolic disorders. This medication should not be administered to patients undergoing dialysis. It should be administered with caution in patients who are dehydrated or have impaired kidney function due to the risk of blood pressure reduction or kidney damage; regular monitoring of their condition is necessary. Particularly in elderly patients or those on diuretics, special caution is needed due to a higher risk of fluid loss and hypotension. The glycemic control effect may vary according to renal function, and it is not recommended for patients with severely impaired kidney function. During the use of this medication, there may be an increased risk of genital infections and urinary tract infections, and immediate treatment should be sought if symptoms appear. There is a risk of hypoglycemia; thus, dose adjustments may be necessary when used in conjunction with insulin or sulfonylureas which can induce hypoglycemia. This medication can cause dehydration or hypotension due to reduced fluid volume, so it should be temporarily discontinued and consulted with a physician if dehydration symptoms occur. Diabetic ketoacidosis may rarely occur, so immediate medical attention should be sought if symptoms such as nausea, vomiting, abdominal pain, or difficulty breathing arise. Serious infections such as necrotizing fasciitis have been reported rarely, and immediate medical care should be sought if there is pain, redness, or swelling around the genital area. Pregnant women or those planning to become pregnant should not take this medication, and breastfeeding women should also avoid it. There are no specific antidotes for overdose, and appropriate treatment should be administered based on symptoms, following physician instructions. This medication does not significantly affect driving or machine operation abilities, but caution is required when taken with other medications that may induce hypoglycemia. The safety and efficacy in children have not been established, and it is recommended not to use it for this age group. When storing this medication, keep it out of reach of children and in its original container.

Side effects

Vulvovaginitis, balanitis and related genital infections, urinary tract infections, fungal infections, perineal necrosis, hypoglycemia, decreased fluid volume, dry mouth, diabetic ketoacidosis, dizziness, constipation, xerostomia, back pain, dysuria, polyuria, nocturia, renal tubule nephritis, vulvar itching, genital itching, increased hematocrit, decreased creatinine clearance at the start of treatment, dyslipidemia, increased serum creatinine at the beginning of treatment, increased blood urea, weight loss, rash, angioedema, acute pyelonephritis, asthenia, pain, keratitis, chronic obstructive pulmonary disease, hemoptysis, cerebral hemorrhage, peripheral artery occlusion, angina, myocardial infarction, bile duct stones, cholangitis, alcoholic liver cirrhosis, depression, suicide attempt, gastric adenocarcinoma, anaphylaxis, paresthesia, cerebral infarction, nerve compression, diverticulitis, pelvic inflammatory disease, pneumonia, pulmonary tuberculosis, ligament sprain, road traffic accident, drug overdose, ankle fracture, hand fracture, iliac bone fracture, meniscus injury, thoracic vertebra fracture, tibia fracture, urticaria, sweating, dermatitis, xerosis, hyperkeratosis, skin lesions, flank pain, fibromyalgia, limb discomfort, muscle cramps, musculoskeletal discomfort, osteopenia, dry eye, eye pain, retinal disorders, vision deterioration, blepharitis, cataracts, conjunctival edema, allergic conjunctivitis, conjunctivitis, diplopia, eyelid edema, keratitis, ocular hypertension, visual disturbances, vitreous floaters, oropharyngeal pain, allergic rhinitis, asthma, voice disorders, epistaxis, sleep apnea syndrome, wheezing, arteriosclerosis, flushing, peripheral coldness, varicose veins, vascular headache, orthostatic hypotension, atrial fibrillation, diastolic dysfunction, palpitations, anxiety disorders, nocturia, hallucinations, sleep disorders, insomnia, fatty liver, gallbladder polyp, tinnitus, anal genital warts, gastric adenoma, neurilemoma, unspecified pituitary neoplasm, male hypogonadism, thyroid cyst, thyroid nodule, food allergy, erythrocytosis, dyspepsia, nausea, diarrhea, vomiting, urinary retention, increased alanine aminotransferase, increased aspartate aminotransferase, decreased appetite, somnolence, headache, nasopharyngitis, upper respiratory infection, chest pain, fatigue, chest discomfort, peripheral edema, generalized edema, hunger, vaginal discharge, menstrual irregularities, itching, arthralgia, musculoskeletal pain, limb pain, muscle weakness, myalgia, osteoarthritis, ligament sprain, diabetic retinopathy, cough, dyspnea, palpitations

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air or moisture, so it must be stored in a tightly sealed container. It is also safe to store at room temperatures between 1 and 30 degrees Celsius, avoiding excessively hot or cold places.

Appearance and packaging

Appearance

Yellow, film-coated tablet with a two-sided convex diamond shape

Package unit

28 tablets/PTP [28 tablets (7 tablets/PTP x 4)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.